Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Dec 22, 2021 (5 years ago)

Gatifloxacin Ophthalmic Solution

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Gatifloxacin Ophthalmic Solution, 0.5%, 2.5 mL bottle, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.) 454 775, INDIA, NDC 68180-435-01.

Affected NDC 68180-0435-01

Compare with the code on your package — it is the most precise check available.

Drug: Gatifloxacin Category: Eye Drops & Ophthalmic

Recalling firm
Lupin Pharmaceuticals Inc.
NDC code
68180-435-01
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0326-2022 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Gatifloxacin recalls

See all
Class II · Moderate risk

Pred Acetate / Gatifloxacin 1% / 0.5% Susp

Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.

Ongoing Sterility / contamination Pharmacy Plus, Inc. dba Vital Care Compounder D-0051-2023
Class III · Low risk

Gatifloxacin Ophthalmic Solution

Failed Stability Specifications: Out-of-specification results observed in a water loss test that might affect the assay content and alter drug concentration.

Terminated Stability / shelf life Lupin Pharmaceuticals Inc. NDC 68180-435-01 D-0091-2022

Other recalls by Lupin Pharmaceuticals Inc.

All 2021 recalls